PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11139287-6	2000	Topotecan, a novel topoisomerase I inhibitor, induced upregulation of TRAIL-R2 as well as downregulation of TRAIL.	Topotecan	0-9	TNF receptor superfamily member 10b	Homo sapiens	70-78	
15719269-4	2005	Our data show that gliomas preferentially express TRAIL R2 and that treatment with topotecan, a topoisomerase I inhibitor, significantly up-regulates its expression as detected by flow cytometry and western blotting.	Topotecan	83-92	TNF receptor superfamily member 10b	Homo sapiens	50-58	
12811515-12	2003	Furthermore, the increase in TRAIL/Apo-2L sensitivity following topotecan treatment correlated with increased expression of TRAIL-R1 and TRAIL-R2 and decreased intracellular levels of the antiapoptotic protein survivin.	Topotecan	64-73	TNF receptor superfamily member 10b	Homo sapiens	137-145	
12811515-14	2003	The sensitivity of DU-145 cells to TRAIL/Apo-2L was dramatically increased when combined with topotecan, suggesting that low-dose topotecan treatment to upregulate TRAIL-R1 and TRAIL-R2 and downregulate survivin, followed by TRAIL/Apo-2L administration, may be a viable therapy for treating cancer of the prostate.	Topotecan	130-139	TNF receptor superfamily member 10b	Homo sapiens	177-185